Two drugs from Hunan Jiudian Pharmaceutical (300705.SZ) have been approved to conduct clinical trials.
Nine Dimension Pharmaceutical (300705.SZ) announced that the company recently received the "Clinical Trial Authorization" issued by the National Medical Products Administration.
Hunan Jiudian Pharmaceutical (300705.SZ) announced that the company has recently received a "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, and will conduct clinical trial research after completing relevant preparation work. The approved clinical trials include: JIZM01 for closed soft tissue contusions and joint sprains, and JIZM02 for shoulder periarticular inflammation.
Related Articles
YAN PALACE (01497) spent HK$307,900 to repurchase 40,000 shares on September 24th.
DREAMEAST(00593): Court approves the withdrawal of an unauthorized Tianyang Qianan shareholder change.
OpenAI is considering renting chips from NVIDIA Corporation (NVDA.US) in order to save 10%-15% of its expenses.
YAN PALACE (01497) spent HK$307,900 to repurchase 40,000 shares on September 24th.
DREAMEAST(00593): Court approves the withdrawal of an unauthorized Tianyang Qianan shareholder change.
OpenAI is considering renting chips from NVIDIA Corporation (NVDA.US) in order to save 10%-15% of its expenses.
RECOMMEND
Annualized Rates Can Exceed 100% — The Allure of Overseas Expansion for Internet Finance
24/09/2025
Significant Money‑Market Signal Emerges as HIBOR Hits Four‑Month High — What It Means for Hong Kong Equities
24/09/2025
A‑Share Firms Accelerating HKEX Filings as Electronics and Power Equipment Lead Submissions
24/09/2025
